Three small-cap potential winners the market has missed
Professional investor Stuart Widdowson of the Odyssean Investment Trust, picks three smaller UK stocks that are trading at a discount to their intrinsic value.
One way investors can reduce risk is by buying assets trading at a discount to their intrinsic value. Several metrics can be used to determine the value of a business, including the price/earnings (p/e) and price-to-book value (p/b) ratios. Two others are Ebitda (earnings before interest, tax and amortisation) and Enterprise Value-to-Ebitda. The process can be more complex if a company has several operating divisions, which may have different attributes and prospects. The sum of private market valuations – the value that a trade or private-equity buyer would pay to acquire control – for each division may be higher than the valuation of the whole company, producing a discount to a “sum of the parts” valuation.
These discounts can narrow for several reasons. The stockmarket, driven by news or a shift in sentiment, can change its view of the valuation of the company; boards can unlock shareholder value by disposing of one or more divisions; or an investor identifies the opportunity and bids for the company. Below are three examples of smaller British firms that we believe are trading at notable discounts to their potential sum-of-the parts valuations.
A pharma group ripe for partition
Clinigen (Aim: CLIN), a pharmaceutical services and products group, has three divisions, built up through mergers and acquisitions (M&A) since its initial public offering in 2014. The shares trade at a forward p/e multiple of ten compared with a five-year average of 16. While there is some logic in keeping its three divisions together, each would appeal to different trade buyers. In our view, the current valuation is sufficiently attractive to interest a financial bidder, who could either integrate the divisions further or undertake a controlled break-up over time.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Cash-rich chemicals
Elementis (LSE: ELM) is a speciality chemicals firm with three “core” divisions and several smaller business units. There is some customer overlap among the core businesses. The current rating of ten times forward earnings is depressed owing to the impact of Covid-19 on its sales and relatively high borrowings. But these will fall over time as the company is very cash-generative. Disposal of one of the smaller, non-core business units would accelerate debt reduction, simplify the story and support a share-price rerating.
Making money in a media niche
Euromoney Institutional Investor (LSE: ERM) is a niche media firm providing companies with financial information. It consists of three divisions. The jewel in its crown is its pricing division, which is based on a subscription model and has grown well over recent years. M&A multiples for similar assets imply that one of the other two divisions is being completely overlooked by the market. Euromoney postponed plans to sell the asset management division earlier this year, but we suspect it will revisit this decision.
Private equity has acquired similar business-media companies over the last couple of decades. The forward p/e is just over 14, assuming some recovery from the trough. We believe that Euromoney’s profit recovery will continue for several years and the stock could again trade at its peak of £15 within four years, implying ample upside from here. The company has no debt and the capacity to pay a good dividend.
-
Why pension transfers are so trickyInvestors could lose out when they do a pension transfer, as the process is fraught with risk and requires advice, says David Prosser
-
The political economy of Clarkson’s FarmOpinion Clarkson’s Farm is an amusing TV show that proves to be an insightful portrayal of political and economic life, says Stuart Watkins
-
How to profit from the UK leisure sector in 2026The UK leisure sector had a straitened few years but now have cash in the bank and are ready to splurge. The sector is best placed to profit
-
Who won the streaming wars?The battle of the TV and film streaming giants for dominance looks to be entering a final phase. The likely winner may surprise you, says Simon Wilson
-
'Investors should expect a good year for equities'Opinion The economy is positive, and investors are still cautious, says Max King
-
8 of the best properties for sale with indoor gymsThe best properties for sale with indoor gyms – from a four-storey mews house in London’s Knightsbridge, to a 1920s Arts & Crafts house in Melbury Abbas, Dorset
-
Top stock ideas for 2026 that offer solidity and growthLast year’s stock ideas from MoneyWeek’s columnist and trader, Michael Taylor, produced another strong performance. This year’s stocks look promising too
-
Market predictions for 2026: Will Dubai introduce an income tax?Opinion My 2026 predictions, from a supermarket merger to Dubai introducing an income tax and Britain’s journey back to the 1970s
-
Stock markets have a mountain to climb: opt for resilience, growth and valueOpinion Julian Wheeler, partner and US equity specialist, Shard Capital, highlights three US stocks where he would put his money
-
The steady rise of stablecoinsInnovations in cryptocurrency have created stablecoins, a new form of money. Trump is an enthusiastic supporter, but its benefits are not yet clear
